Peter Kojo Quashie
ASSOCIATE PROFESSOR
CollegeCOLLEGE OF BASIC & APPLIED SC.
School / InstituteCOLLEGE OF BASIC & APPLIED SC.
DepartmentWEST AFRICAN CENTRE FOR CELL BIOLOGY OF INFECTIOUS PATHOGENS
Virology
Publication activity
Publication statistics
Publications
114 matching publications
| Publication | Year | Journal | Thematic area | Citations |
|---|---|---|---|---|
| Abstract O324ÁTable 1. Relative rate (RR) of receipt of each of the four interventions in women versus men, before and after adjustment for potential confounders (age, year … M Wainberg, K Anstett, T Mesplede, P Quashie, Y Han, M Oliveira |
2014 | OPEN ACCESS OPEN ACCESS 17, 21, 2014 | Natural Sciences | 0 |
| Evolution of HIV integrase resistance mutations: Erratum PK Quashie, T Mesplede, MA Wainberg |
2014 | CURRENT OPINION IN INFECTIOUS DISEASES 27 (3), 302-302, 2014 | Health Sciences | 0 |
| Primary mutations in HIV integrase that confer resistance to raltegravir (RAL) and elvitegravir (EVG) are incompatible with the R263K mutation that is associated with low-level … K Anstett, T Mesplede, P Quashie, Y Han, M Oliveira, MA Wainberg |
2014 | ANTIVIRAL THERAPY 19, A149-A149, 2014 | Health Sciences | 0 |
| Evidence for the importance of G118R in integrase inhibitor therapy in different subtypes PK Quashie, T Mesplede, T Veres, S Hassounah, W Huang, ... |
2013 | ANTIVIRAL THERAPY 18, A36-A36, 2013 | Natural Sciences | 0 |
| Identification of novel HIV-1 integrase inhibitors with excellent resistance profiles from natural products YS Han, PK Quashie, T Mesplede, HT Xu, HD Sun, MA Wainberg |
2013 | Antiviral Therapy 18, A109-A109, 2013 | Health Sciences | 0 |
| Secondary mutations in the R263K in vitro pathway of resistance against dolutegravir fail to restore integration and viral fitness T Mesplede, PK Quashie, MA Wares, N Osman, Y Han, DN Singhroy, ... |
2013 | ANTIVIRAL THERAPY 18, A107-A107, 2013 | Health Sciences | 0 |
| A high-throughput assay for HIV-1 integrase 3′-processing activity using time-resolved fluorescence. HYS Han YingShan, P Quashie, T Mesplede, XHT Xu HongTao, ... |
2012 | — | Health Sciences | 0 |
| Dolutegravir MA Wainberg, PK Quashie, T Mesplede |
2012 | Drugs of the Future 37 (10), 2012 | Natural Sciences | 0 |
| HIV gp120 H375 is unique to CRF01_AE HIV-1 and confers resistance to the entry 1 inhibitor BMS-599793, a candidate microbicide drug. 2 SM Schader, SP Colby-Germinario, PK Quashie, M Oliveira |
2012 | — | Health Sciences | 0 |
| Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. XHT Xu HongTao, EL Asahchop, M Oliveira, PK Quashie, ... |
2011 | — | Health Sciences | 0 |
| O332 The R263K mutation in HIV integrase that is selected by dolutegravir (DTG) may actually prevent clinically relevant resistance to this compound M Wainberg, K Anstett, T Mesplede, P Quashie, Y Han, M Oliveira, ... |
1900 | — | Health Sciences | 0 |
| ORAL PAPERS–PART TWO C Smith, L Ryom, A d’Arminio Monforte, P Reiss, A Mocroft, W El-Sadr, ... |
1900 | — | Natural Sciences | 0 |
| Population-Level Biological Protection against Severe COVID-19 in West Africa: Findings from a 20,748-Participant Multi-Country Phased Seroepidemiology Study A Udoakang, D Oduro-Mensah, G Amegatcher, O Folarin, IA Aliyu, ... |
1900 | — | Natural Sciences | 0 |
| RESISTANCE–PART ONE A Schultze, R Paredes, C Sabin, A Phillips, D Pillay, O Kirk, J Lundgren, ... |
1900 | — | Natural Sciences | 0 |